

January 20, 2026

To,  
**BSE Limited**  
Department of Corporate Services  
Phiroze Jeejeebhoy Towers  
Dalal Street, Fort  
Mumbai- 400 001  
**Scrip Code: 516110**

**Sub: Integrated Filing (Financial) for the Third quarter ended 31st December 2025**

Respected Sir/Madam,

In terms of provisions of Regulation 10(1A) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated 31 December 2024, and BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated 2 January 2025; the Integrated Filing (Financial) for the Third quarter ended 31<sup>st</sup> December 2025 is enclosed herewith.

We request you to kindly take this on record.

Thanking You,

Yours Faithfully,

**For Family Care Hospitals Limited**

Suchit  
Raghunath  
Modshing

Digitally signed by Suchit Raghunath  
Modshing  
DN: c=IN, o=Personal, title=3814,  
serialNumber=72624759664Cdbca460d8e  
5142713a,  
2.5.4.20=63a7833c096d672a207818c2  
5233a12c979768ec21726aaba5f,  
postalCode=401105, st=Maharashtra,  
serialNumber=16a48ba4c7546df0b017  
6ae386572a0d48db7853a887c0443a7907  
5d878, cn=Suchit Raghunath Modshing  
Date: 2026.01.20 19:50:37 +05'30'

**Suchit Raghunath Modshing**  
**WholeTime Director**  
**DIN: 10974977**  
**Encl: a/a**

A. Financial Result – Annexure A

B. Statement on deviation or variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement etc.: **Applicable**

Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)	
Mode of Fund Raising	Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)	
Date of Raising Funds	26-12-2025
Amount Raised	466.94
Report filed for Quarter ended	31-12-2025
Monitoring Agency	Not applicable
Monitoring Agency Name, if applicable	
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	
If Yes, Date of shareholder Approval	
Explanation for the Deviation / Variation	NA
Comments of the Audit Committee after review	NA
Comments of the auditors, if any	NA

Objects for which funds have been raised and where there has been a deviation, in the following table:

Sr.	Original Object	Modified Object, if any	Original Allocation	Modified allocation, if	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable	Remarks if any
<div> <div>Add</div> <div>Delete</div> </div>							
1	25% of the total issue, i.e. ₹46,693,750, has been received and the same has been utilized for working capital purposes	NA	46693750.00	0.00	46693750.00	0.00	Add Details

C. Format for disclosing outstanding default on Loans and Debt Securities: **Not Applicable as we don't have any default on loans and debt securities outstanding as on December 31, 2025.**

Sr. No.	Particulars	in ₹ crore
<b>1.</b>	<b>Loans / revolving facilities like cash credit from banks / financial institutions</b>	
<b>A</b>	Total amount outstanding as on date	<b>0</b>
<b>B</b>	Of the total amount outstanding, amount of default as on date	<b>0</b>
<b>2.</b>	<b>Unlisted debt securities i.e. NCDs and NCRPS</b>	
<b>A</b>	Total amount outstanding as on date	<b>0</b>
<b>B</b>	Of the total amount outstanding, amount of default as on date	<b>0</b>
<b>3.</b>	<b>Total financial indebtedness of the listed entity including short term and long-term debt</b>	<b>0</b>

D. Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter): **Not Applicable for this Quarter**

E. Statement on Impact of Audit Qualifications (for Audit Report with modified opinion) submitted along-with annual Audited Financial Results (Standalone) (applicable only for Annual Filing i.e., 4th quarter): **Not Applicable for this Quarter**



**LIMITED REVIEW REPORT FOR QUARTER AND NINE MONTH ENDED  
31st December, 2025**

To,  
The Board of Directors,  
**Family Care Hospitals Limited.**  
(Formerly known as Scandent Imaging Limited)  
Plot No. 357, Road No. 26,  
Wagle Industrial Estate,  
MIDC, Thane (West) – 400604

**Re: Report on financial Results for the Quarter and Nine Month ended 31st December, 2025**

1. We have reviewed the accompanying statement of unaudited financial results of **FAMILY CARE HOSPITALS LIMITED** ('the company') for the Quarter and Nine Month ended 31st December, 2025 ('the Statement') attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
2. This statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review in accordance with Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data, and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



**4. Attention is invited to the following:**

We draw attention to Note 3 of the accompanying financial results, which describes as, Compay has issued Share Warrant of 1,86,77,500 on a preferential allotment basis pursuant to provisions of SEBI (Issue of Capital and Disclosure Requirement) Regulation 2018. Out of the issue, company has received of Rs. 4,66,93,750 (including Dealmoney Commodities Pvt Ltd of Rs. 4,50,00,000 being 25 % of the issue price) till 31<sup>st</sup> December, 2025. The balance amount shall be received at the time of exercise of the share warrant.

Our conclusion is not qualified in respect of above matters

5. Based on our review conducted as above, except for the matters to which attention is drawn above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Financial Results, prepared in accordance with the applicable Indian Accounting Standards specified under Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Yours faithfully,

**Rafik and Associates**  
Chartered Accountants  
ICAI FRN 146573W  
RAFIK SEJAM SHEIKH  
SHEIKH  
Digitally signed by  
RAFIK SEJAM SHEIKH  
Date: 2026.01.20  
19:00:04 +05'30'  
**Rafik Sejam Sheikh**  
**Proprietor**  
**Membership No: 182278**

**Date: 20<sup>th</sup> January, 2026**

**Place: Mumbai**

**Udin:- 26182278ZSNQKE4893**

**FAMILY CARE HOSPITALS LIMITED**

**CIN : L93000MH1994PLC080842**

**Statement of Unaudited Financial Results for the Quarter and Nine Months Ended December 31, 2025**

[Figures in ₹ lakhs unless stated otherwise]

Sr. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2025	30.09.2025	31.12.2024	31.12.2025	31.12.2024	31.03.2025
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from Operations	6.01	7.38	2.83	15.11	788.03	790.46
2	Other Income	2.81	10.41	0.04	13.22	112.46	315.22
3	<b>Total Income (1 + 2)</b>	<b>8.82</b>	<b>17.79</b>	<b>2.87</b>	<b>28.34</b>	<b>900.48</b>	<b>1,105.68</b>
4	<b>Expenses</b>						
	Purchase of Stock-In-Trade	5.18	0.32	(0.15)	5.49	63.88	63.88
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	65.99	-	(3,752.64)	(3,752.64)
	Employee Benefits Expense	12.61	11.34	27.48	34.72	195.71	217.76
	Finance Costs	8.29	9.75	6.62	25.55	21.69	28.54
	Depreciation and Amortisation Expense	22.20	22.64	28.03	67.97	87.77	112.64
	Other Expenses	56.30	434.46	84.50	520.58	1,335.66	1,420.15
	<b>Total Expenses (4)</b>	<b>104.56</b>	<b>478.51</b>	<b>212.46</b>	<b>654.31</b>	<b>(2,047.93)</b>	<b>(1,909.66)</b>
5	<b>Profit / (Loss) before exceptional items and tax (3 - 4)</b>	<b>(95.74)</b>	<b>(460.72)</b>	<b>(209.59)</b>	<b>(625.98)</b>	<b>2,948.41</b>	<b>3,015.34</b>
6	Exceptional items	-	-	-	-	(7,462.00)	(7,462.00)
7	<b>Profit / (Loss) before tax (5 + 6)</b>	<b>(95.74)</b>	<b>(460.72)</b>	<b>(209.59)</b>	<b>(625.98)</b>	<b>(4,513.59)</b>	<b>(4,446.66)</b>
8	<b>Tax Expense</b>						
	(a) Current Tax	-	-	-	-	-	-
	(b) Deferred Tax Credit / (Charge)	-	-	-	-	-	(32.13)
	(c) Earlier Year	-	-	-	-	-	-
9	<b>Profit / (Loss) for the year (7 - 8)</b>	<b>(95.74)</b>	<b>(460.72)</b>	<b>(209.59)</b>	<b>(625.98)</b>	<b>(4,513.59)</b>	<b>(4,414.53)</b>
10	<b>Other Comprehensive income</b>						
	<b>(a) (i) Items that will not be reclassified to Profit or Loss</b>						
	Re-measurement of defined benefit plans	-	-	-	-	-	12.48
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	<b>(b) (i) Items that will be reclassified to Profit or Loss</b>	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	<b>Other Comprehensive income for the year (10)</b>	-	-	-	-	-	12.48
11	<b>Total Comprehensive income for the year (9 + 10)</b>	<b>(95.74)</b>	<b>(460.72)</b>	<b>(209.59)</b>	<b>(625.98)</b>	<b>(4,513.59)</b>	<b>(4,402.05)</b>
12	<b>Paid-up equity share capital (Face Value - ₹ 10 per share)</b>	5,401.48	5,401.48	5,401.48	5,401.48	5,401.48	5,401.48
13	<b>Earnings Per Share (of ₹ 10/- each) (not annualised):</b>						
	<b>Basic earnings per share ₹</b>	(0.18)	(0.85)	(0.39)	(1.16)	(8.36)	(8.17)
14	<b>Earnings Per Share (of ₹ 10/- each) (not annualised):</b>						
	<b>Diluted earnings per share ₹</b>	(0.18)	(0.85)	(0.39)	(1.16)	(8.36)	(8.17)

**Notes:**

1	The Statement of financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015, Companies (Indian Accounting standards) (Amendment) Rules, 2016 and other accounting principles generally accepted in India. There is no minority interest.
2	The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on January 20, 2026 and have been review by the Statutory auditors of the Company.
3	During the quarter, the Company has received Rs. 4,66,93,750/-, including Dealmoney Commodities Private Limited Rs. 4,50,00,000/- being 25% of the issue price, pursuant to the preferential allotment of 18,677,500 share warrants on a preferential basis, in accordance with the provisions of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. The balance amount shall be received at the time of exercise of the warrants.
4	Segment reporting as per Indian Accounting Standard 108 is not applicable as Company operates only in one segment i.e, Healthcare Services.
5	Previous years / periods figures have been regrouped or reclassified wherever necessary to make them comparable with the figures of the current period.

**For and on behalf of the board of Directors  
Family Care Hospitals Limited**

Suchit  
Raghunath  
Modshing

**Suchit Modshing  
Whole-Time Director  
DIN No. 10974977**

**Place : Thane  
Date : 20-Jan-2026**